Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for thrombocytopenia prevention in high-risk sarcoma
NCT00038311Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2000
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human thrombopoietin in Thrombocytopenia, sponsored by Pfizer. Primary endpoint: Cumulative proportion of patients with severe chemotherapy-induced thrombocytopenia. Started Sep 2000; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00038311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038311.